Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 373 followers
Latest posts
Last updated 5 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
5 days ago
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated...
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
7 days ago
The filing application is based on improvements seen across key efficacy endpoints...
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
8 days ago
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost...
Invitation to Roche’s Half Year Results 2026 Presentation
13 days ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
19 days ago
Filing acceptance based on data from the phase III SUNMO study where...
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
26 days ago
Filing acceptance is based on the phase III Alliance ATOMIC study showing...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
29 days ago
Agreement offers potential best-in-class targeted protein degrader therapy option for people living...
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
about 1 month ago
Filing acceptance, under priority review, based on phase III data showing giredestrant...
Reminder: Invitation to Roche’s Virtual ADA Investor Event
about 1 month ago
We are pleased to invite investors and analysts to participate in our...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
about 1 month ago
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its...
Reminder: Invitation to Roche’s Investor Event at ASCO 2026
about 2 months ago
The Roche Investor Relations team would like to invite you to an...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
about 2 months ago
New giredestrant data from the lidERA study on its potential as a...